aTyr Pharma Inc
NASDAQ:ATYR
aTyr Pharma Inc
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel immunological pathways. The company is headquartered in San Diego, California and currently employs 49 full-time employees. The company went IPO on 2015-05-07. Its therapeutic candidate pipeline includes efzofitimod (ATYR1923), ATYR2810, NRP2 mAbs, AARS-1 and DARS-1. The ATYR1923, is a fusion protein comprised of the immunomodulatory domain of histidyl-tRNA synthetase fused to the fragment crystallizable (Fc) region of a human antibody and serves as a selective modulator of NRP2 that downregulates innate and adaptive immune response in inflammatory disease states. The firm is also developing efzofitimod as a potential disease-modifying therapy for patients with fibrotic lung diseases with high unmet medical need. ATYR2810 is a fully humanized monoclonal antibody that specifically and functionally blocks the interaction between NRP2 and one of its primary ligands VEGF. ATYR2810 is in preclinical development for the potential treatment of certain aggressive cancers where NRP2 is implicated.
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel immunological pathways. The company is headquartered in San Diego, California and currently employs 49 full-time employees. The company went IPO on 2015-05-07. Its therapeutic candidate pipeline includes efzofitimod (ATYR1923), ATYR2810, NRP2 mAbs, AARS-1 and DARS-1. The ATYR1923, is a fusion protein comprised of the immunomodulatory domain of histidyl-tRNA synthetase fused to the fragment crystallizable (Fc) region of a human antibody and serves as a selective modulator of NRP2 that downregulates innate and adaptive immune response in inflammatory disease states. The firm is also developing efzofitimod as a potential disease-modifying therapy for patients with fibrotic lung diseases with high unmet medical need. ATYR2810 is a fully humanized monoclonal antibody that specifically and functionally blocks the interaction between NRP2 and one of its primary ligands VEGF. ATYR2810 is in preclinical development for the potential treatment of certain aggressive cancers where NRP2 is implicated.
Phase III Study Progress: aTyr completed enrollment in its pivotal global Phase III EFZO-FIT trial for efzofitimod in pulmonary sarcoidosis, with top-line data expected in Q3 2024.
Primary Endpoint Change: After FDA feedback, the primary endpoint will now measure steroid reduction as the absolute change from baseline to week 48, rather than average daily dose post-taper—powering remains over 90%.
Market Opportunity: New data suggest the US sarcoidosis market is larger than previously thought, with nearly 75% of patients prescribed steroids and a possible $2–5 billion global ILD market opportunity.
Safety Profile: The EFZO-FIT trial has passed four DSMB reviews with no safety concerns, reinforcing efzofitimod’s favorable safety profile.
Financial Runway: With $75.1 million in cash at year-end 2024 and an additional $18.8 million raised, aTyr expects to fund operations through one year after Phase III EFZO-FIT readout.
Research Recognition: The mechanism of action for efzofitimod was published in Science Translational Medicine, strengthening scientific validation.
Scleroderma Study: Interim skin data from the Phase II efzofitimod trial in systemic sclerosis ILD (SSC-ILD) is expected in Q2 2024.
